Abstract |
Interleukin-13 receptor alpha2 (IL-13Ralpha2) is a glioma-restricted cell-surface epitope not otherwise detected within the central nervous system. The present study is a report of a novel approach of targeting malignant glioma with IL-13Ralpha2-specific cytotoxic T lymphocyte (CTL) induced from the peripheral blood mononuclear cells of healthy donors by multiple stimulations with human leukocyte antigen (HLA)-A2-restricted IL-13Ralpha2(345-353) peptide-pulsed T2 cells. The induced CTL showed specific lysis against T2 cells pulsed with the peptide and HLA-A2+ glioma cells expressing IL-13R2(345-353), while HLA-A2 glioma cell lines that express IL-13Ralpha2(345-353) could not be recognized by CTL. The peptide-specific activity was inhibited by anti-HLA class I monoclonal antibody. These results suggest that the induced CTL specific for IL-13Ralpha2(345-353) peptide could be a potential target of specific immunotherapy for HLA-A2 patients with malignant glioma.
|
Authors | Xiaobing Jiang, Xiaoling Lu, Ru'en Liu, Fangcheng Zhang, Hongyang Zhao |
Journal | Acta biochimica et biophysica Sinica
(Acta Biochim Biophys Sin (Shanghai))
Vol. 39
Issue 9
Pg. 641-8
(Sep 2007)
ISSN: 1672-9145 [Print] China |
PMID | 17805458
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- HLA-A2 Antigen
- Interleukin-13 Receptor alpha2 Subunit
- Peptides
|
Topics |
- Cell Line
- Cell Line, Tumor
- Coculture Techniques
- Glioma
(immunology, pathology)
- HLA-A2 Antigen
(immunology)
- Humans
- Immunophenotyping
- Interleukin-13 Receptor alpha2 Subunit
(biosynthesis, genetics, immunology)
- Lymphocyte Activation
(immunology)
- Peptides
(immunology, metabolism)
- T-Lymphocytes, Cytotoxic
(immunology, metabolism)
|